Best Organ-On-A-Chip Companies

Emulate develops an automated bio-emulation platform. It offers a brain chip, a colon-intestine chip, a duodenum-intestine chip, a kidney chip, a liver chip, and more. The company was founded in 2014 and is based in Boston, Massachusetts.

InSphero provides pharmaceutical and biotechnology services. It focuses on industrial-grade, three-dimensional (3D)-cell-based assay solutions, and organ-on-a-chip technology for pharmaceutical drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases, diabetes, and Immuno oncology. InSphero was founded in 2009 and is based in Schlieren, Switzerland.

CN Bio provides micro-physiological systems that enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems. Providing efficiencies for pre-clinical drug testing with predictive human tissue-based data, the company’s technologies are able to replicate the micro-environments, cell-cell interactions and biological processes that occur in vivo, to bridge the gap between traditional cell culture assays and human studies, improving drug discovery while reducing research and development costs.

Hubrecht Organoid Technology (HUB) is a biotechnology company that provides development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. It is based in Utrecht, Nederland.

Altis Biosystems develops a stem cell technology that recreates the human intestinal epithelium in a 2D or 3D layer of human intestinal stem and differentiated cells, either of the small or large intestine. The company was founded in 2015 and is based in Durham, North Carolina.

AxoSim facilitates preclinical prediction of neurological safety and efficacy early in the drug development pipeline. Employing microengineering techniques and biomaterials, the company has developed a 3D cell-based model which mimics living tissue in both form and function. By providing an alternative to exploratory animal testing, pharmaceutical companies will have access to high content data faster and earlier than currently possible.

BiomimX develops eating organs-on-chip platforms designed as drug screening tools. Its products include uBeat, which supports the culture of three independent 3D microtissue models within a single device that comprises of uBeat Stretch, which provides uniaxial stretching deformation; uBeat Compress, which provides specific levels of confined compression; and uBox, which is the control system that provides the mechanical stimulation to each uBeat platform. The company was founded in 1986 and is based in Milano, Italy.

BI/OND the versatile Organ-on -chip platform. BI/OND Empowers biologists with hardware solutions for cell-based assays. BI/OND’s customizable Organ-on-Chips (OOCs) are built to outperform the limitation of standard in vitro assays.

Dynamic42 de­vel­ops, of­fers and cus­tomizes novel 3D mi­cro­phys­i­o­log­i­cal in vit­ro test sys­tems recre­at­ing hu­man or­gan key func­tions. It integrates immune system components for the research and testing of pharmaceutical products and forms of therapy such as nanoparticles, chemicals, and food additives. The company was founded in 2018 and is based in Jena, Germany.

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its microfluidic technology enables testing of drug compounds in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation. MIMETAS develops and validates customised disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.

Neuro Engineering Technologies Research Institute (NETRI) creates disruptive technologies for organs-on-chips applications in neuroscience. The company investigates ex-vivo complex neuronal architectures that emulate human brain circuits – for understanding how neurological troubles, treatments, and chemicals affect the human brain.

Pregenerate provides products and services to replace expensive and inefficient animal testing in medical and pharmaceutical research. The company focuses on global degenerative joint disease, osteoarthritis, which not only affects the aging human population but also sport horses and companion animals. The company uses scaleable organ-on-a-chip models to replace animal testing in pharmaceutical research for arthritis treatments.

Quris AI is a pharmaceutical artificial intelligence firm that develops a clinical prediction AI platform that helps predict which drug candidates will safely work in humans, assisting in ensuring the safety and efficacy of new drugs and the repurposing and personalization of existing drugs. Its Bio-AI Clinical Prediction Platform generates proprietary data and uses machine learning to predict clinical safety and efficacy. The company was founded in 2019 and is based in Tel- Aviv Israel.

Xilis operates as a biotechnology company for the treatment of cancer patients. It provides MicroOrganoSphere (MOS) platform that enables personalized rapid diagnostics for immuno-oncology. Its technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. The company was founded in 2019 and is based in Durham, North Carolina.